Log in

NASDAQ:NTUSNatus Medical Stock Price, Forecast & News

+0.40 (+1.93 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: $21.15
50-Day Range
MA: $21.80
52-Week Range
Now: $21.15
Volume132,200 shs
Average Volume288,901 shs
Market Capitalization$714.87 million
P/E Ratio58.75
Dividend YieldN/A
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing screening products; diagnostic hearing assessment products to screen for/or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. Additionally, it offers jaundice management products; brain injury products; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Pleasanton, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.88 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:NTUS



Sales & Book Value

Annual Sales$495.52 million
Cash Flow$2.13 per share
Book Value$12.21 per share


Net Income$-15,670,000.00


Market Cap$714.87 million
Next Earnings Date7/30/2020 (Confirmed)

Receive NTUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NTUS and its competitors with MarketBeat's FREE daily newsletter.

Natus Medical (NASDAQ:NTUS) Frequently Asked Questions

How has Natus Medical's stock been impacted by COVID-19 (Coronavirus)?

Natus Medical's stock was trading at $27.18 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NTUS shares have decreased by 22.2% and is now trading at $21.15. View which stocks have been most impacted by Coronavirus.

When is Natus Medical's next earnings date?

Natus Medical is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Natus Medical.

How can I listen to Natus Medical's earnings call?

Natus Medical will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Natus Medical's earnings last quarter?

Natus Medical Incorporated (NASDAQ:NTUS) announced its quarterly earnings results on Thursday, April, 30th. The company reported $0.04 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.22 by $0.18. The company had revenue of $109.40 million for the quarter, compared to the consensus estimate of $115 million. Natus Medical had a return on equity of 9.91% and a net margin of 2.51%. Natus Medical's revenue for the quarter was down 4.9% on a year-over-year basis. View Natus Medical's earnings history.

Has Natus Medical been receiving favorable news coverage?

News stories about NTUS stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Natus Medical earned a coverage optimism score of 1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Natus Medical.

Are investors shorting Natus Medical?

Natus Medical saw a decline in short interest in June. As of June 30th, there was short interest totaling 1,030,000 shares, a decline of 9.6% from the June 15th total of 1,140,000 shares. Based on an average trading volume of 348,900 shares, the short-interest ratio is currently 3.0 days. Approximately 3.1% of the shares of the stock are sold short. View Natus Medical's Current Options Chain.

Who are some of Natus Medical's key competitors?

What other stocks do shareholders of Natus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natus Medical investors own include Gilead Sciences (GILD), NovaBay Pharmaceuticals (NBY), Pfizer (PFE), AbbVie (ABBV), Carnival (CCL), Costco Wholesale (COST), Johnson & Johnson (JNJ), Marathon Petroleum (MPC), Netflix (NFLX) and Philip Morris International (PM).

Who are Natus Medical's key executives?

Natus Medical's management team includes the following people:
  • Mr. Jonathan A. Kennedy CPA, Pres, CEO & Director (Age 48)
  • Mr. Benjamin Drew Davies, Exec. VP & CFO (Age 53)
  • Mr. Austin F. Noll III, Exec. VP & Chief Commercial Officer (Age 52)
  • Mr. Seán Langan, VP Global Operations
  • Mr. Ivan Pandiyan, VP of Global R&D

What is Natus Medical's stock symbol?

Natus Medical trades on the NASDAQ under the ticker symbol "NTUS."

Who are Natus Medical's major shareholders?

Natus Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Confluence Investment Management LLC (0.45%). Company insiders that own Natus Medical stock include Dong Chune Christopher Chung and Jonathan Kennedy. View institutional ownership trends for Natus Medical.

Which major investors are selling Natus Medical stock?

NTUS stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC. Company insiders that have sold Natus Medical company stock in the last year include Dong Chune Christopher Chung, and Jonathan Kennedy. View insider buying and selling activity for Natus Medical.

How do I buy shares of Natus Medical?

Shares of NTUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Natus Medical's stock price today?

One share of NTUS stock can currently be purchased for approximately $21.15.

How big of a company is Natus Medical?

Natus Medical has a market capitalization of $714.87 million and generates $495.52 million in revenue each year. The company earns $-15,670,000.00 in net income (profit) each year or $1.24 on an earnings per share basis. Natus Medical employs 1,484 workers across the globe.

What is Natus Medical's official website?

The official website for Natus Medical is www.natus.com.

How can I contact Natus Medical?

Natus Medical's mailing address is 6701 KOLL CENTER PARKWAY SUITE 120, PLEASANTON CA, 94566. The company can be reached via phone at 925-223-6700 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.